We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GSK PLC Sponsored ADR (GSK) - free report >>
Novartis AG (NVS) - free report >>
Pfizer Inc. (PFE) - free report >>
Merck & Co., Inc. (MRK) - free report >>
Amgen Inc. (AMGN) - free report >>
Gilead Sciences, Inc. (GILD) - free report >>
Vertex Pharmaceuticals Incorporated (VRTX) - free report >>
iShares Biotechnology ETF (IBB) - free report >>
Biotech ETFs Pop on M&A Resurgence
The biopharma industry has seen a recent upswing in mergers and acquisitions (M&A). Total healthcare and life sciences M&A was about $71 billion in the first quarter of 2023, more than double the $28 billion in the same period last year, according to KPMG.
The Wall Street Journal reported that executives at Pfizer (PFE - Free Report) , Merck (MRK - Free Report) , and Novartis (NVS - Free Report) said they are all looking for new drugs to add to their pipelines as their top-selling products lose patent protection in the coming years.
Big pharma companies are sitting on significant cash piles that they could use for deal-making. According to EY estimates, life sciences companies had more than $1.4 trillion in cash and other capital at the end of 2022, suggesting that 2023 could be a year of heightened industry deal-making activity.
Pfizer's (PFE - Free Report) purchase of Seagen for $43 billion is the largest pharmaceutical deal since AbbVie's acquisition of Allergan in 2019. Seagen produces targeted therapies that seek out and kill cancer cells without harming healthy cells.
Merck plans to acquire Prometheus Biosciences , which is testing promising therapies for immune diseases like ulcerative colitis and Crohn's disease. British pharma giant (GSK - Free Report) agreed to buy buy Bellus Health BLU.
The iShares Biotechnology ETF (IBB - Free Report) is the most popular product in the space. It tracks a market cap weighted index. Vertex Pharmaceuticals (VRTX - Free Report) , Gilead Sciences (GILD - Free Report) and Amgen (AMGN - Free Report) are the top holdings in the fund.
The Invesco Nasdaq Biotechnology ETF IBBQ provides a similar exposure to the sector, but with a lower expense ratio. Launched in 2021, this product has managed to gather only $20 million in assets so far.
The SPDR S&P Biotech ETF (XBI - Free Report) tracks an equal-weighted index and is therefore tilted towards smaller companies.
The ALPS Medical Breakthroughs ETF (SBIO - Free Report) and the Principal Healthcare Innovators ETF BTEC focus on innovative small- and mid-cap biotech companies.
To learn more, please watch the short video above.